2RH0 Stock Overview
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
RedHill Biopharma Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.38 |
| 52 Week High | US$3.58 |
| 52 Week Low | US$0.24 |
| Beta | 3.46 |
| 1 Month Change | -7.14% |
| 3 Month Change | -26.08% |
| 1 Year Change | -82.05% |
| 3 Year Change | -99.84% |
| 5 Year Change | -99.86% |
| Change since IPO | -99.91% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2RH0 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -3.3% | 2.5% | 1.8% |
| 1Y | -82.0% | -27.7% | 2.2% |
Return vs Industry: 2RH0 underperformed the German Pharmaceuticals industry which returned -27.7% over the past year.
Return vs Market: 2RH0 underperformed the German Market which returned 2.2% over the past year.
Price Volatility
| 2RH0 volatility | |
|---|---|
| 2RH0 Average Weekly Movement | 24.1% |
| Pharmaceuticals Industry Average Movement | 6.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 2RH0's share price has been volatile over the past 3 months.
Volatility Over Time: 2RH0's weekly volatility has decreased from 50% to 24% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 53 | Dror Ben-Asher | www.redhillbio.com |
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers’ diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; and RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis.
RedHill Biopharma Ltd. Fundamentals Summary
| 2RH0 fundamental statistics | |
|---|---|
| Market cap | €12.74m |
| Earnings (TTM) | €22.35m |
| Revenue (TTM) | €6.10m |
0.6x
P/E Ratio2.0x
P/S RatioIs 2RH0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2RH0 income statement (TTM) | |
|---|---|
| Revenue | US$6.53m |
| Cost of Revenue | US$3.46m |
| Gross Profit | US$3.07m |
| Other Expenses | -US$20.84m |
| Earnings | US$23.92m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.75 |
| Gross Margin | 47.03% |
| Net Profit Margin | 366.25% |
| Debt/Equity Ratio | 0% |
How did 2RH0 perform over the long term?
See historical performance and comparison